Pfizer launches new biopharmaceutical company to develop Parkinson’s drugs

News

Author: Simge Eva DoganPublished: 7 November 2018

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

Pfizer

Pharmaceutical company Pfizer has teamed with investment firm Bain Capital to launch Cerevel Therapeutics – a biopharmaceutical company focused on developing drugs for Parkinson’s and other central nervous system conditions.

The new company – which will receive US $350 million of investment from Bain Capital – will begin working on phase three clinical trials on a Parkinson’s drug designed to increase levels of dopamine in the brain. Cerevel will also continue to develop several of Pfizer’s drug programmes which closed earlier this year.

Marco Baptista, director of research programmes at The Michael J Fox Foundation – which has partnered with Pfizer since 2010 – said: “This is welcome news for Parkinson’s patients and researchers. Pfizer had developed a diverse group of novel therapeutics for Parkinson’s disease, which are now going to get another chance at success. MJFF looks forward to partnering with Cerevel to support the advancement of these promising programs.”

To read more on this topic click here.

For more information on Parkinson’s treatments please visit the EPDA website


Read more:

AI technology could diagnose Parkinson’s in less than three minutes

New smart glasses could track Parkinson’s symptoms

Go Back

Share this story

Comments


Related articles


Emma Lawton David Sangster PD365 100-day milestone lead

Perspectives

Young-onset daily vlogging duo reach 100th day

What Emma and David learned from 100 days of Parkinson’s vlogging

READ MORE
cloudUPDRS-app-lead

Resources & Tools

Michael J Fox Foundation pledges £100,000 for Parkinson’s app

cloudUPDRS app project receives £100,000 for further development

READ MORE
170612_PL_Billy Connolly mural by John Byrne ii

Perspectives

Billy Connolly “overjoyed” by Glasgow murals

Leading Scottish artists create giant portraits of comedian

READ MORE